Search Results - Lisbeth Enggaard

P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA by Rebecca Teglgaard, Sisse Rye Ostrowski, Caspar Da Cunha-Bang, Christian Brieghel, Tereza Faitová, Lisbeth Enggaard, Hans Jakob Hartling, Hanne Vibeke Hansen Marquart, Carsten Utoft Niemann

Get full text

P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL by Carsten Niemann, Mark-David Levin, Anders Österborg, Jeanette Lundin, Magdalena Kättström, Jeanette Vollerup, Caspar Da Cunha-Bang, Michael Foraux, Christian Brieghel, Fransien de Boer, Lisbeth Enggaard, Christian Bjorn Poulsen, Joanne Reekie, Rudi Agius

Get full text

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL by Arnon Kater, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit Veldhuis, Rogier Mous, Clemens Mellink, Johan Dobber, Christian Poulsen, Caspar Da Cunha-Bang, Hendrik Fredriksen, Ann Janssens, Ida Schjodt, Ellen Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Mark-David Levin, Carsten Niemann

Get full text

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial by Carsten U. Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H.M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Wida Razawy, René Hollestein, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Arnon P. Kater, Mark-David Levin

Get full text